The U.S. Food and Drug Administration (FDA) has granted fast-track designation to the experimental therapy ZW191 as a potential treatment for hard-to-manage ovarian cancer.
News
A European Medicines Agency (EMA) panel has recommended approval of a subcutaneous (under-the-skin) version of Sarclisa (isatuximab), an approved myeloma treatment sold by Sanofi. The…
Merck is set to acquire Terns Pharmaceuticals in a $6.7 billion deal aimed at expanding its oncology pipeline, including an experimental treatment for chronic…
Adding Amplia Therapeutics‘ experimental drug narmafotinib to standard chemotherapy led to complete responses — meaning no detectable cancer on imaging scans for at least…
Myosin Therapeutics has been awarded $2 million in funding to support a Phase 1/2 clinical trial testing its lead experimental cancer therapy, MT-125, in…
Overt Bio said it established a clinical advisory board to support the development of OVT-101, its lead investigational CAR T-cell therapy for ovarian cancer,…
Tempus AI, a technology company focused on advancing precision medicine using artificial intelligence (AI), has announced a strategic collaboration with the advocacy organization…
Caris Life Sciences has launched a new diagnostic tool that aims to help guide treatment decisions for people with pancreatic ductal adenocarcinoma (PDAC), the…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AMXT 1501 to treat malignant…
Researchers have developed a new cell therapy that aims to treat endometrial cancer by targeting cancer cells while also depleting immune cells that help protect…
